…
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -315.00M | 605.00M | 715.00M | 260.40M | 160.30M |
| Minority interest | - | - | - | - | -5.40M |
| Net income | -232.00M | 519.00M | 585.00M | 220.70M | 137.40M |
| Selling general administrative | 884.00M | 884.00M | 687.00M | 577.90M | 512.00M |
| Gross profit | 1060.00M | 1640.00M | 1352.00M | 983.30M | 805.10M |
| Reconciled depreciation | - | 378.00M | 289.00M | 253.70M | 228.60M |
| Ebit | -137.00M | 349.00M | 354.00M | 143.80M | 61.80M |
| Ebitda | 79.00M | 727.00M | 643.00M | 397.50M | 290.40M |
| Depreciation and amortization | 216.00M | 378.00M | 289.00M | 253.70M | 228.60M |
| Non operating income net other | -28.00M | -28.00M | -3.00M | - | -2.70M |
| Operating income | -137.00M | 349.00M | 354.00M | 143.80M | 61.80M |
| Other operating expenses | 4203.00M | 4073.00M | 3352.00M | 2688.90M | 2224.90M |
| Interest expense | 184.00M | 123.00M | 110.00M | 126.10M | 110.90M |
| Tax provision | -83.00M | 86.00M | 130.00M | 39.70M | 22.90M |
| Interest income | - | - | - | - | 110.40M |
| Net interest income | -184.00M | -127.00M | -110.00M | -126.10M | -126.70M |
| Non recurring | - | - | - | - | 19.20M |
| Income tax expense | -83.00M | 86.00M | 130.00M | 39.70M | 22.90M |
| Total revenue | 4276.00M | 4828.00M | 3998.00M | 3094.30M | 2518.00M |
| Total operating expenses | 987.00M | 885.00M | 706.00M | 577.90M | 512.00M |
| Cost of revenue | 3216.00M | 3188.00M | 2646.00M | 2111.00M | 1712.90M |
| Total other income expense net | -204.00M | 256.00M | 361.00M | 116.60M | 98.50M |
| Net income from continuing ops | 499.00M | 519.00M | 585.00M | 220.70M | 183.20M |
| Net income applicable to common shares | 483.00M | 503.00M | 529.00M | 173.00M | 137.40M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 10782.00M | 10507.00M | 9112.00M | 7776.50M | 6184.00M |
| Intangible assets | 980.00M | 1060.00M | 817.00M | 888.70M | 930.80M |
| Other current assets | 658.00M | 70.00M | 376.00M | 177.90M | 76.80M |
| Total liab | 6147.00M | 5712.00M | 5197.00M | 4877.70M | 4502.40M |
| Total stockholder equity | 4635.00M | 4795.00M | 3915.00M | 2898.80M | 1681.60M |
| Deferred long term liab | 197.00M | 202.00M | 164.00M | 2.40M | 74.40M |
| Other current liab | 544.00M | 435.00M | 431.00M | 308.30M | 183.20M |
| Common stock | 2.00M | 2.00M | 2.00M | 1.60M | 1.50M |
| Capital stock | - | 2.00M | 361.00M | 608.20M | 1.50M |
| Retained earnings | 262.00M | 538.00M | 25.00M | -535.20M | -723.40M |
| Other liab | 327.00M | 469.00M | 399.00M | 340.90M | 342.30M |
| Good will | 3039.00M | 3006.00M | 2519.00M | 2470.60M | 2220.90M |
| Other assets | 4404.00M | 4431.00M | 210.00M | 122.00M | 99.80M |
| Cash | 280.00M | 449.00M | 896.00M | 953.20M | 345.40M |
| Total current liabilities | 1507.00M | 1072.00M | 1196.00M | 893.20M | 670.70M |
| Current deferred revenue | - | 185.00M | 305.00M | 191.00M | 155.20M |
| Net debt | 4569.00M | 3753.00M | 2345.00M | 2064.80M | 2613.90M |
| Short term debt | 536.00M | 31.00M | 75.00M | 72.90M | 76.50M |
| Short long term debt | 536.00M | 31.00M | 75.00M | 72.90M | 76.50M |
| Short long term debt total | 4849.00M | 4202.00M | 3241.00M | 3018.00M | 2959.30M |
| Other stockholder equity | 4701.00M | -5858.00M | 3846.00M | 3212.10M | 2150.80M |
| Property plant equipment | 3127.00M | 3127.00M | 2524.00M | 2002.20M | 1536.70M |
| Total current assets | 2679.00M | 2916.00M | 2918.00M | 2293.00M | 1395.80M |
| Long term investments | - | 33.00M | 38.00M | - | - |
| Net tangible assets | 709.00M | 729.00M | 938.00M | -460.50M | -863.50M |
| Short term investments | 89.00M | 89.00M | 71.00M | - | - |
| Net receivables | 977.00M | 1051.00M | 1012.00M | 838.10M | 716.40M |
| Long term debt | 4171.00M | 4171.00M | 3166.00M | 2945.10M | 2882.80M |
| Inventory | 764.00M | 702.00M | 563.00M | 323.80M | 257.20M |
| Accounts payable | 427.00M | 421.00M | 385.00M | 321.00M | 255.80M |
| Accumulated other comprehensive income | -354.00M | -394.00M | -317.00M | -386.30M | -353.90M |
| Common stock total equity | 2.00M | 2.00M | 2.00M | 1.60M | 1.50M |
| Retained earnings total equity | 518.00M | 538.00M | 25.00M | - | -723.40M |
| Non currrent assets other | 4404.00M | 316.00M | 230.00M | 3582.70M | 3251.50M |
| Deferred long term asset charges | - | - | - | - | 38.60M |
| Non current assets total | 8103.00M | 7591.00M | 6194.00M | 5483.50M | 4788.20M |
| Capital lease obligations | - | 14.00M | 16.00M | - | - |
| Long term debt total | 4171.00M | 4171.00M | 3166.00M | - | 2882.80M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -22.00M | -22.00M | -649.00M | -827.50M | 1.80M |
| Change to liabilities | 37.00M | 37.00M | 50.00M | 72.20M | 36.20M |
| Total cashflows from investing activities | -1884.00M | -1884.00M | -649.00M | -827.50M | -1510.40M |
| Net borrowings | 1007.00M | 1007.00M | 80.00M | 48.30M | 124.20M |
| Total cash from financing activities | 521.00M | 1031.00M | 142.00M | 1001.70M | 1201.40M |
| Change to operating activities | - | -448.00M | -36.00M | 33.80M | -43.60M |
| Net income | -256.00M | 519.00M | 585.00M | 220.70M | 137.40M |
| Change in cash | -169.00M | -447.00M | -57.00M | 607.80M | -64.80M |
| Begin period cash flow | 449.00M | 896.00M | 953.00M | 345.40M | 410.20M |
| End period cash flow | 280.00M | 449.00M | 896.00M | 953.20M | 345.40M |
| Total cash from operating activities | 261.00M | 439.00M | 433.00M | 440.30M | 247.70M |
| Issuance of capital stock | - | 0.00M | 82.00M | 1046.50M | 1091.80M |
| Depreciation | 422.00M | 378.00M | 289.00M | 253.70M | 228.60M |
| Other cashflows from investing activities | -1202.00M | -1196.00M | -147.00M | - | -1290.50M |
| Dividends paid | 4.00M | -4.00M | -22.00M | -36.20M | 36.20M |
| Change to inventory | -192.00M | -128.00M | -260.00M | -76.40M | -34.00M |
| Change to account receivables | 53.00M | -73.00M | -186.00M | -150.90M | -118.90M |
| Sale purchase of stock | 26.00M | 26.00M | 202.00M | 909.10M | 1091.80M |
| Other cashflows from financing activities | 751.00M | 751.00M | -53.00M | -56.90M | 2054.60M |
| Change to netincome | 121.00M | 126.00M | -79.00M | 74.80M | 9.90M |
| Capital expenditures | 583.00M | 660.00M | 686.00M | 465.80M | 218.10M |
| Change receivables | -73.00M | -73.00M | -186.00M | - | -118.90M |
| Cash flows other operating | -399.00M | -424.00M | 16.00M | - | -16.90M |
| Exchange rate changes | - | - | 17.00M | - | -3.50M |
| Cash and cash equivalents changes | -414.00M | -414.00M | -57.00M | - | -64.80M |
| Change in working capital | -160.00M | -612.00M | -432.00M | -121.30M | -160.30M |
| Stock based compensation | 35.00M | 54.00M | 51.00M | 48.10M | 33.30M |
| Other non cash items | 347.00M | 86.00M | -124.00M | 36.70M | 23.80M |
| Free cash flow | -322.00M | -221.00M | -253.00M | -25.50M | 29.60M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Mr. John R. Chiminski | Exec. Chair of the Board | 1964 |
| Mr. Alessandro Maselli | CEO & Director | 1972 |
| Mr. Thomas P. Castellano | Sr. VP & CFO | 1980 |
| Mr. Steven L. Fasman Esq. | Exec. VP, Corp. Sec. & Chief Admin. Officer | 1963 |
| Dr. Aristippos Gennadios Ph.D. | Group Pres of Pharma & Consumer Health Segment | 1966 |
| Mr. Ricky Hopson | Pres & Division Head for Clinical Devel. and Supply | 1976 |
| Ms. Karen Murphy Santiago | VP & Chief Accounting Office | 1971 |
| Mr. Julien Meissonnier | VP & Chief Scientific Officer | NA |
| Mr. Charles Lickfold | Sr. VP & Chief Information Officer | 1974 |
| Mr. Paul Surdez | VP of Investor Relations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.